CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy is a significant advancement in cancer immunotherapy.
• It has demonstrated success in treating B-cell leukemias and lymphomas.

Purpose of the Study:

• To review current innovations in CAR T-cell strategies for hematologic and solid tumors.
• To discuss challenges and novel approaches like CAR T-cell-derived nanovesicles.

Main Methods:

• Review of existing literature on CAR T-cell therapy.
• Analysis of genetic engineering techniques for T cells.
• Exploration of new CAR T-cell strategies and nanovesicle applications.

Main Results:

• CAR T-cell therapy shows remarkable responses in certain blood cancers.
• Significant hurdles include severe toxicities (e.g., cytokine release syndrome) and limited efficacy in other malignancies.
• Innovations focus on enhancing anti-tumor activity and managing side effects.

Conclusions:

• CAR T-cell therapy holds great potential but requires further development for broader application.
• Addressing toxicity and improving efficacy in solid tumors are key research areas.
• Emerging strategies like nanovesicle therapy may offer new therapeutic avenues.